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Available online 12 December 2016Objective: Hippocampal atrophy has been associated with mild cognitive impairment (MCI) in Parkinson's dis-
ease (PD). However, literature onhowhippocampal atrophy affects thepathophysiology of cognitive impairment
in PD has been limited. Previous studies assessed the hippocampus as an entire entity instead of their individual
subregions.We studied the progression of cognitive status in PD subjects over 18 in relation to hippocampal sub-
fields atrophy.
Methods: 65 PD subjects were included. Using the MDS task force criteria, PD subjects were classified as either
having no cognitive impairment (PD-NCI) or PD-MCI. We extended the study by investigating the hippocampal
subfields atrophy patterns in those who converted from PD-NCI to PD-MCI (PD-converters) compared to those
who remained cognitively stable (PD-stable) over 18months. Freesurfer 6.0 was used to perform the automated
segmentation of the hippocampus into thirteen subregions.
Results: PD-MCI showed lower baseline volumes in the left fimbria, right CA1, and right HATA; and lower global
cognition scores compared to PD-NCI. Baseline right CA1 was also correlated with baseline attention. Over
18 months, decline in volumes of CA2–3 and episodic memory were also seen in PD-converters compared to
PD-stable. Baseline volumes of GC-DG, right CA4, left parasubiculum, and left HATA were predictive of the con-
version from PD-NCI to PD-MCI.
Conclusion: The findings from this study add to the anatomical knowledge of hippocampal subregions in PD,
allowing us to understand the unique functional contribution of each subfield. Structural changes in the hippo-
campus subfields could be early biomarkers to detect cognitive impairment in PD.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Cognitive impairment1. Introduction
Parkinson's disease (PD), the secondmost common neurodegenera-
tive disorder, is characterized by motor and non-motor symptoms
(Hanganu et al., 2014). Cognitive impairment is an important feature
of non-motor symptoms in PD affecting around 25% of newly diagnosed
patients (Ibarretxe-Bilbao et al., 2012) and it can be observed in the
early stages of the disease (Pereira et al., 2013). Up to 80% of PD patients
without cognitive impairment, eventually develop mild cognitive im-
pairment (PD-MCI) and dementia (Aarsland et al., 2003). Consequen-
tially, this has important implications in disease management, whichal-amygdaloid transition region.
titute, 11 Jalan Tan Tock Seng,
Kandiah).
. This is an open access article underunderscores the need to establish biomarkers that could allow for the
early identification of PD patients at risk of developing dementia.
The neuropathological mechanisms underlying cognitive deficits in
PD remain to be clearly understood. In the recent years, emerging data
have altered the traditional view that the hippocampus is not implicat-
ed in PD, except for its possible implications in dementia, to the hypoth-
esis that suggests a pivotal role of hippocampal synaptic plasticity in
memory in PD patients (Pereira et al., 2013; Calabresi et al., 2013).
While there is a general agreement that hippocampal atrophy is associ-
ated with impaired memory in PD (Calabresi et al., 2013; Brück et al.,
2004; Kandiah et al., 2014; Camicioli et al., 2003), previous studies in-
vestigated hippocampus as a single structure. However, the hippocam-
pus is not a homogeneous structure but consist of several subfields with
distinct histological characteristics and specific pathway that interplay
to affect the memory (Mueller et al., 2010). This implies that the
cytoarchitecture of the individual hippocampal subfields have differentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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gression of cognitive impairment and dementia in PD. Therefore, study-
ing hippocampal subfields may be a significant biomarker to detect
cognitive impairment in PD. Moreover, previous studies investigating
the effects of hippocampal atrophy on PD patients were mainly cross-
sectional measurement, which precludes the ability of these studies to
detect subtle changes in the hippocampus due to between-subject var-
iance. Therefore, in this present study,we seek to obviate these issues by
investigating thehippocampus in their distinct subfields using serial im-
aging, which could allow us to study the progression of atrophy in the
hippocampal subfields in PD.
In this study, we investigated the baseline characteristics and hippo-
campal subfields volumes in PD-NCI and PD-MCI subjects. Subsequent-
ly, we extended the study to examine the progression of hippocampal
subfields atrophy in PD-NCI subjects who either remained cognitively
stable (PD-stable) or thosewho converted into PD-MCI (PD-converters)
over 18 months. We further examined the predictive utility of baseline
hippocampal subfield volumes in determining the conversion of cogni-
tive status from PD-NCI to PD-MCI. Correlations between the atrophy of
hippocampal subfields and cognitive andmotor declinewere also inves-
tigated. Based on a previous cross-sectional study investigating hippo-
campal subfields in Alzheimer's disease using FreeSurfer, which
demonstrated that MCI patients showed smaller CA1 and CA2 regions
compared to controls (Mueller et al., 2010), we postulate that specific
hippocampal subfields rather than whole hippocampal volume may
be more useful in predicting cognitive impairment in PD subjects. As
such, we hypothesize that PD-MCI would be characterized by specific
baseline reduction of hippocampal subfields compared to PD-NCI; and
that specific baseline volumes of hippocampal subfields would also be
useful in predicting the conversion from PD-NCI to PD-MCI over
18 months.
2. Methods
2.1. Subjects
Between August 2011 and March 2012, 85 subjects from a tertiary
neurology centre were recruited and followed up for 18 months. Over
the course of the study duration, 19 subjects withdrew and one de-
ceased. Only subjects (n = 65) with baseline and follow-up were in-
cluded in this study. Parkinson's disease was diagnosed by movement
disorder specialists according to the National Institute of Neurological
Disorders and Stroke (NINDS) criteria (Gelb et al., 1999). Inclusion
criteria included literate subjects with mild PD, defined by Hoehn and
Yahr staging of b3, aged between 50 and 90years. Subjectswith demen-
tia, or serious medical and psychiatric co-morbidities were excluded
from the study. The study was approved by the Singhealth institutional
ethics review board and informed consent was obtained for all subjects.
2.2. Assessments
Subjects underwent clinical and neuropsychological evaluations as
well as MRI imaging at baseline and month 18. Clinical evaluations in-
cluded medical history, Unified PD Rating Scale (UPDRS) to ascertain
subjects' motor and functional abilities, and Hoehn and Yahr to deter-
mine the stage of the disease.
Neuropsychological assessments of global cognition included the
Mini-Mental State Examination (MMSE) (Folstein et al., 1975) and
Montreal Cognitive Assessment (MoCA) (Dalrymple-Alford et al.,
2010). In addition, in accordance with MDS Task Force recommenda-
tions (Litvan et al., 2012), five cognitive domainswere assessed. Episod-
ic memory was assessed with word-list delayed and recognition recall
from the Alzheimer's Disease Assessment Scale-cognitive subscale
(ADAS-Cog); executive function was assessed with the 10-point clock
drawing and frontal assessment battery (FAB); attention was assessed
with digit span and colour trails 1; visuospatial function was assessedwith figure copy test and number of errors made on a Maze test in
ADAS-Cog; and language was assessed with comprehension of test in-
structions from ADAS-Cog and fluency assessment (Saumier et al.,
2009). Performance on individual tasks was transformed into z-scores
and a composite summary index for each cognitive domain was
then derived from the corresponding averages of the individual
neuropsychological tests. Changes in memory domains were calculated
using the following formula: (memory domainfollow-up – memory
domainbaseline).
Subjects were classified as PD-MCI withMovement Disorder Society
(MDS) level 2 criteria if they were impaired (1.5 SD) below the norma-
tive means on at least two cognitive tests as represented by either im-
pairment of 2 tests in one domain or impairment of one test in two
different domains. Subjects who did not fulfill the above criteria were
classified as PD-NCI. Using the same criteria as aforementioned, we fur-
ther classified PD-NCI subjects into: those who converted to PD-MCI
(PD-converters) and thosewho remained cognitively stable (PD-stable)
over 18 months.
2.3. Image acquisition
All subjects underwent both baseline and repeat MRI with a mean
18-month interval on a 3 Tesla GE scanner system. A high-resolution
T1-weighted MPRAGE (axial acquisition, 176 slices, matrix size =
256 × 256, voxel size = 1.0 × 1.0 × 1.0 mm3, TE = 3.2 ms, TR = 7 ms,
TI = 850 ms, flip angle 8°, field of view 256 × 256 mm2) was acquired
for all subjects.
2.4. 2.4 image analysis
Cortical reconstruction and volumetric segmentation were per-
formed using FreeSurfer 6.0 image analysis suit (http://surfer.nmr.
mgh.harvard.edu/). The technical details have been described previous-
ly (Fischl andDale, 2000). In summary, image processing procedures in-
clude the following steps: motion correction and average of multiple
volumetric T1-weighted images, removal of non-brain tissue, automat-
ed Talairach transformation, intensity normalization, segmentation of
the subcortical white matter and deep grey matter volumetric struc-
tures, tessellation of the grey matter and white matter boundary, auto-
mated topology correction, and surface deformation to optimally place
the grey/white and grey/cerebrospinal fluid boundaries (Reuter et al.,
2012). All surface models were inspected for accuracy and manual cor-
rections were performed in the event of tissue misclassification and/or
white matter errors while blinded to the diagnostic information.
For longitudinal processing, an unbiased within-subject template
space (Reuter and Fischl, 2011) and imagewas created using robust, in-
verse consistent registration (Reuter et al., 2012). The following steps,
which included skull stripping, Talairach transformations, atlas registra-
tion, spherical surface maps and parcellation to initialize with common
information from within-subject template, were taken to significantly
increase reliability and statistical power. The cortical thickness was cal-
culated as the closest distance from the grey/white matter boundary to
the grey/CSF boundary at each vertexwhile total greymatter volume in-
cludes both surface-based volume calculations and voxel counts.
Total hippocampal volumes were obtained from the automated
pipeline for volumetric segmentation of subcortical structures imple-
mented in FreeSurfer for both baseline and follow-up. Subsequently,
the hippocampal subfields were segmented using a Bayesian inference
approach and a novel atlas algorithm of the hippocampal formations
built primarily upon ultra-high resolution (~0.1 mm isotropic) ex
vivo MRI data from autopsy brains (Iglesias et al., 2015). The left and
right hippocampi were segmented into thirteen subfields: alveus,
parasubiculum, presubiculum, subiculum, CA1, CA2–3, CA4, granule
cell layer of dentate gyrus (GC-DG), hippocampus-amygdala-transi-
tion-area (HATA), fimbria, molecular layer, hippocampal fissure, hippo-
campal tail (Fig. 1). This presented atlas was more sensitive than the
Fig. 1. Hippocampal subfields in a coronal view of a PD subject.
Table 1
Baseline subject characteristics and hippocampal subfields volumes of PD-NCI and PD-MCI.
PD-NCI
(N = 54)
PD-MCI
(N = 11)
p-Value
Subjects' baseline characteristics
Ageb 63.39 ± 6.86 69.45 ± 10.19 0.017
Gender (Male, %)a 41 (75.9%) 6 (54.55%) χ2 = 2.086, p= 0.149
Educationc 10.93 ± 3.40 9.73 ± 2.97 0.653
Disease durationb 4.74 ± 3.02 4.09 ± 3.39 0.431
Scan intervalb 1.31 ± 0.14 1.39 ± 0.22 0.625
APOE4a (Yes, %) 11 (20.37%) 2 (18.18%) χ2 = 1.609, p= 0.447
Diabetesa (Yes, %) 8 (14.81%) 3 (27.27%) χ2 = 1.009, p= 0.379
Hypertensiona
(Yes, %)
20 (37.04%) 4 (36.36%) χ2 = 0.002, p = 0.966
Hyperlipidemiaa
(Yes, %)
24 (44.44%) 7 (63.64) χ2 = 1.349, p= 0.327
Smoking historya
(Yes, %)
19 (35.19%) 3 (27.27%) χ2 = 0.256, p = 0.737
LEDDc 621.20 ± 447.38 633.88 ± 452.27 0.803
Motor characteristics (Baseline)
Hoehn and Yahrc 2.08 ± 0.41 2.00 ± 0.59 0.762
UPDRS IIIc 18.95 ± 8.96 15.27 ± 5.26 0.667
Neuroimaging characteristics
Cortical thickness
LHb
2.19 ± 0.10 2.19 ± 0.11 0.878
Cortical thickness
RHb
2.18 ± 0.10 2.18 ± 0.11 0.856
Total GM volb 518.85 ± 37.56 509.46 ± 48.11 0.474
Memory domains (Baseline)
Global cognitionc 0.10 ± 0.90 −0.62 ± 1.11 0.013
Episodic Memoryc 0.14 ± 0.88 −0.06 ± 0.47 0.121
Executivec 0.15 ± 0.67 −0.37 ± 1.02 0.130
Attentionb −0.04 ± 0.64 0.28 ± 0.63 0.140
Visuospatialc 0.09 ± 0.58 −0.48 ± 1.40 0.210
Languagec 0.09 ± 0.77 −0.29 ± 0.89 0.074
Hippocampal subfields LH (Baseline)d
Hippocampal tail 0.50 ± 0.06 0.50 ± 0.08 0.227
Subiculum 0.41 ± 0.05 0.41 ± 0.07 0.265
CA1 0.57 ± 0.07 0.59 ± 0.10 0.066
Hippocampal fissure 0.16 ± 0.05 0.16 ± 0.02 0.861
Presubiculum 0.29 ± 0.04 0.29 ± 0.05 0.332
Parasubiculum 0.06 ± 0.03 0.05 ± 0.01 0.503
Molecular Layer 0.52 ± 0.08 0.53 ± 0.08 0.220
GC-DG 0.28 ± 0.04 0.27 ± 0.04 0.874
CA2–3 0.20 ± 0.03 0.20 ± 0.03 0.858
CA4 0.24 ± 0.03 0.23 ± 0.03 0.861
Fimbria 0.09 ± 0.02 0.07 ± 0.01 0.048
HATA 0.06 ± 0.01 0.05 ± 0.01 0.870
Whole Hippocampus 3.24 ± 0.31 3.21 ± 0.50 0.221
Hippocampal subfields RH (Baseline)d
Hippocampal tail 0.57 ± 0.33 0.51 ± 0.09 0.777
Subiculum 0.42 ± 0.05 0.42 ± 0.06 0.174
CA1 0.63 ± 0.09 0.60 ± 0.07 0.031
Hippocampal fissure 0.18 ± 0.06 0.18 ± 0.03 0.908
Presubiculum 0.28 ± 0.04 0.28 ± 0.05 0.207
Parasubiculum 0.06 ± 0.03 0.05 ± 0.01 0.409
Molecular Layer 0.54 ± 0.08 0.56 ± 0.07 0.108
GC-DG 0.30 ± 0.04 0.30 ± 0.04 0.356
CA2–3 0.22 ± 0.03 0.22 ± 0.03 0.402
CA4 0.25 ± 0.03 0.25 ± 0.03 0.181
Fimbria 0.08 ± 0.03 0.06 ± 0.01 0.130
HATA 0.06 ± 0.01 0.05 ± 0.005 0.011
Whole Hippocampus 3.32 ± 0.54 3.37 ± 0.45 0.186
Values expressed as Mean ± SD.
Cognitive scores were Z-scored.
Abbreviations: APOE, Apolipoprotein E; LEDD indicates levodopa equivalent dose; UPDRS,
Unified Parkinson's Disease Rating Scale; LH, Left hemisphere; RH, Right hemisphere; CA,
cornu ammonis; GC-DG, granule cell layer of dentate gyrus; HATA, hippocampus-amygda-
la-transition-area.
a χ2 (df = 1).
b Indepedent samples t-test (df = 63).
c Mann-Whitney test.
d ANCOVA (df = 1) controlling for age, gender, education, intracranial volume with
post-hoc Bonferroni pairwise test.
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hippocampal subfields as it allowed for greater accuracy in the delinea-
tion of the boundaries within the subfields (Iglesias et al., 2015). Subse-
quently, percentage changes in the volumes between two time points in
hippocampal longitudinal changes were calculated using the following
formula: [(volumefollow-up− volumebaseline)/volumebaseline] * 100%.
2.5. Statistical analysis
Statistical analyses were performed using Statistical Package for the
Social Sciences (SPSS) version 20.0 (SPSS, Inc.; Chicago, IL, USA).
Skweness-Kurtosis and visual inspection of histogramwere used to ex-
amine normality for continuous variables. Demographic differences be-
tween the two groupswere examined using independent samples t-test
or Mann-Whitney U test depending on the normality of distributions;
and chi-square test for categorical variables. Comparisons of hippocam-
pal subfields were assessed using analysis of covariance (ANCOVA)
followed by post-hoc pairwise Bonferroni tests. Additionally, we per-
formed partial correlations to investigate the associations between hip-
pocampal subfields and memory functions. Logistic regression was also
performed to investigate the predictive utility of baseline hippocampal
subfield volumes in the conversion from PD-NCI to PD-MCI over
18 months. All volumetric analyses in this study were corrected for
age, gender, education, and intracranial volumes. Results with a two-
tailed probability value of b0.05 were considered significant.
3. Results
3.1. Baseline subject characteristics and hippocampal subfields volumes of
PD-NCI and PD-MCI
Table 1 summarizes the baseline clinical, neuropsychological, and
neuroimaging information of PD-NCI and PD-MCI. 65 subjects were
classified as follow: 54 PD-NCI and 11 PD-MCI. The subjects were well
matched in their baseline demographic and clinical characteristics,
except that subjects with PD-MCI were significantly older than PD-
NCI. PD-NCI and PD-MCI also showed no significant differences in
baseline cortical thickness and grey matter volumes. PD-MCI showed
lower baseline global cognition scores compared to PD-NCI. More
Table 2
Longitudinal subject characteristics and hippocampal subfields volumes of PD-stable and
PD-converters.
PD-stable
(N = 42)
PD-converters
(N = 12)
p-Value
Subjects' baseline characteristics
Ageb 63.19 ± 7.21 64.08 ± 5.65 0.696
Gender (Male, %)a 32 (76.19%) 9 (75.0%) χ2 = 0.007, p = 0.932
Educationc 10.83 ± 3.41 11.25 ± 3.49 0.712
Disease durationb 4.57 ± 3.01 5.36 ± 3.10 0.431
Scan intervalb 1.31 ± 0.14 1.29 ± 0.14 0.625
APOE4a (Yes, %) 8 (19.05%) 3 (25%) χ2 = 0.463, p = 0.793
Diabetesa (Yes, %) 8 (19.05%) 0 (0%) χ2 = 2.683, p= 0.176
Hypertensiona
(Yes, %)
18 (42.86%) 2 (16.67%) χ2 = 2.745, p= 0.098
Hyperlipidemiaa
(Yes, %)
20 (47.62%) 4 (33.33%) χ2 = 0.771, p = 0.515
Smoking historya
(Yes, %)
14 (33.33%) 5 (41.67%) χ2 = 0.284, p = 0.734
LEDDc 621.20 ± 447.37 633.88 ± 452.27 0.803
Motor characteristics (Change)
Hoehn and Yahrc −0.05 ± 0.35 −0.11 ± 0.18 0.606
UPDRS IIIc 0.26 ± 0.92 0.28 ± 0.55 0.289
Memory domains (Change)
Global cognition 0.51 ± 0.34 0.02 ± 0.31 0.632
Epsodic Memoryc 0.20 ± 0.69 −0.70 ± 0.69 0.013
Executivec 0.12 ± 0.89 −0.56 ± 1.02 0.055
Attentionb −0.02 ± 0.66 0.12 ± 0.58 0.105
Visuospatialc −0.16 ± 1.13 −0.16 ± 0.70 0.934
Languagec −0.15 ± 1.27 0.11 ± 0.43 0.269
Neuroimaging characteristics (Change)
Cortical thickness LHb −0.42 ± 1.89 0.12 ± 1.49 0.369
Cortical thickness RHb 0.29 ± 2.13 0.27 ± 1.47 0.978
Total GM volb −0.60 ± 1.83 −1.04 ± 0.85 0.577
Hippocampal subfields LH (Change)d
Hippocampal tail −0.70 ± 4.62 −1.94 ± 4.34 0.714
Subiculum −1.99 ± 2.48 −1.82 ± 1.70 0.952
CA1 −1.33 ± 4.35 −2.78 ± 2.49 0.418
Hippocampal fissure −0.29 ± 7.56 −2.05 ± 5.94 0.501
Presubiculum −1.71 ± 4.11 −2.46 ± 3.59 0.729
Parasubiculum −0.99 ± 8.28 −1.55 ± 5.17 0.932
Molecular layer −2.11 ± 2.80 −1.76 ± 2.36 0.534
GC-DG −1.89 ± 4.05 −2.61 ± 3.07 0.808
CA2–3 −1.31 ± 5.22 −4.52 ± 3.40 0.121
CA4 −1.83 ± 4.30 −2.59 ± 2.83 0.802
Fimbria −1.21 ± 4.98 0.98 ± 6.42 0.095
HATA −0.61 ± 5.48 −0.64 ± 10.32 0.944
Whole hippocampus −1.87 ± 2.40 −2.63 ± 1.99 0.545
Hippocampal subfields RH (Change)d
Hippocampal tail −1.35 ± 4.45 −0.98 ± 1.67 0.631
Subiculum −1.41 ± 3.23 −1.05 ± 4.09 0.976
CA1 −1.24 ± 3.89 −2.19 ± 2.17 0.553
Hippocampal fissure −1.83 ± 5.83 −1.06 ± 8.19 0.752
Presubiculum −0.98 ± 3.48 −0.44 ± 3.21 0.759
Parasubiculum −0.52 ± 4.72 −1.11 ± 3.76 0.766
Molecular layer −1.54 ± 3.07 0.04 ± 2.68 0.062
GC-DG −0.15 ± 4.04 −0.21 ± 3.25 0.755
CA2–3 0.33 ± 5.15 −3.81 ± 3.69 0.029
CA4 0.37 ± 3.85 −0.96 ± 4.17 0.490
Fimbria −5.50 ± 10.42 −6.01 ± 15.80 0.683
HATA −3.95 ± 7.90 −3.94 ± 6.38 0.929
Whole hippocampus −1.45 ± 2.69 −1.70 ± 1.53 0.904
Values expressed as Mean ± SD.
Cognitive scores were Z-scored.
Abbreviations: APOE, Apolipoprotein E; LEDD indicates levodopa equivalent dose; UPDRS,
Unified Parkinson's Disease Rating Scale; LH, Left hemisphere; RH, Right hemisphere;
CA, cornu ammonis; GC-DG, granule cell layer of dentate gyrus; HATA, hippocampus-
amygdala-transition-area.
a χ2 (df = 1).
b Indepedent samples t-test (df = 63).
c Mann-Whitney test.
d ANCOVA (df = 1) controlling for age, gender, education, intracranial volume with post-
hoc Bonferroni pairwise tests. Change in memory domains = follow-up visit− baseline;
Change in imaging data = [(volumefollow-up− volumebaseline) / volumebaseline] * 100%.
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PD-MCI had lower volumes in the left fimbria, right CA1, and right
HATA regions compared to PD-NCI. Baseline right CA1 volume also
showed partial correlations with baseline attention (r = 0.273, p =
0.038, df = 56).
3.2. Longitudinal subject characteristics and hippocampal subfields vol-
umes of PD-stable and PD-converters
Over 18 months, within the PD-NCI group (n = 54) at baseline, 42
subjects remained cognitively stable and were classified as PD-stable
while 12 subjects developed MCI and were classified as PD-converters.
Table 2 shows the change in clinical, neuropsychological, and neuroim-
aging information of these subjects. The groups were well matched in
their demographic and clinical characteristics. PD-converters, however,
showed greater decline in episodic memory over 18 months. PD-con-
verters also showed greater atrophy in the right CA2–3 overtime com-
pared to PD-stable (Table 2, p b 0.05).
Additional logistic regression analyses also showed that decreasing
baseline volumes of GC-DG (left p = 0.049; right p = 0.040), right
CA4 (p = 0.026), left parasubiculum (p = 0.023), and left HATA (p =
0.022) increased the likelihood of the conversion from PD-NCI to PD-
MCI over 18 months, after controlling for age, education, gender, and
ICV.
4. Discussion
The main findings of this study were: (i) At baseline, PD-MCI
showed lower volumes in the left fimbria, right CA1, and right HATA to-
gether with lower global cognition scores compared to PD-NCI; (ii)
Baseline right CA1 was significantly associated with baseline attention
scores; (iii) PD-converters showed greater atrophy in the CA2–3 and
episodic memory deficits compared to PD-stable over 18 months; (iv)
Baseline volumes of GC-DG, right CA4, left parasubiculum, and left
HATA were predictive of the conversion from PD-NCI to PD-MCI over
18 months.
To date, only a few studies have investigated the role of regional hip-
pocampal atrophy in PD; as such the neuropathological mechanisms of
hippocampus in modulating cognition in PD, have not been well eluci-
dated. A previous neuropathological study has shown that the extent
of deposition of Lewy bodies and Lewy neuritis in the hippocampus
was associated to the severity of cognitive impairment in PD, implying
that hippocampus structures play an important role in cognition in PD
(Churchyard and Lees, 1997). Previous neuroimaging studies using vol-
umetric analyses have also supported the association between cognitive
impairment and hippocampal atrophy in PD (Ibarretxe-Bilbao et al.,
2012; Carlesimo et al., 2012). However, a study by Apostolova et al.
(2010) did not find any hippocampal contribution to cognition in PD
after correcting for age (Apostolova et al., 2010). The heterogeneity in
findings could be due in part to the variability ofmethods used to exam-
ine the hippocampus. Furthermore, within the paucity of hippocampal
literature in PD, only Beyer et al. (2013) and Pereira et al. (2013) have
assessed precise measurements of the specific subfields within the
hippocampus in PD subjects. The former showed associations between
delayed recall and subfield areas of CA1, CA3 and subiculum, and
short-term recall with CA1 and subiculum; whereas the latter demon-
strated that CA2–3 and CA4-DG subfields had greater volume loss in
the PD group compared to controls. Although these studies specifically
assessed structures within the hippocampus compared to studies
assessing regional hippocampal atrophy, they were however limited
by their cross-sectional designs.
Hippocampus is a complex structure where the neuroanatomical
organization and interconnections between the subfields could influ-
ence the pathophysiological and cognitive processes in PD subjects.
Considering the functional specialization of the histologically distinct
hippocampal subregions, local analyses of the hippocampus subregions
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cytoarchitecture of these areas in thepathologenesis of PD and cognitive
impairment (Mak et al., 2016). In light of this, we first explored the
baseline volumes of hippocampal subfields in PD-NCI and PD-MCI; we
then examined the cognitive progression in PD-NCI (PD-stable or PD-
converters) in affecting the longitudinal impact of atrophy in the indi-
vidual subfields of the hippocampus.
PD-MCI showed reduced volumes in CA1 at baseline compared to
PD-NCI and correlated significantly with baseline attention scores.
This study was consistent with previous studies showing that CA1 was
one of the earliest sites within the hippocampus to be affected, which
was associatedwith increased risk for conversion fromMCI to dementia
(Beyer et al., 2013). Similarly, previous post-mortem and imaging stud-
ies have showed that degenerations within CA1 and subiculum were
more severe in MCI than in dementia (Braak and Braak, 1997; Lim et
al., 2013). In addition, at a molecular level, animal studies have shown
that alterations in the glutamatergic transmission might cause the de-
fect in CA1 hippocampal long-term potentiation, which could in turn
contribute to dopamine-dependent impairment and thereby, resulting
in cognitive deficits in PD (Calabresi et al., 2013). This implies that the
interplay of glutamatergic and dopaminergic deficiencies in CA1 could
cause cognitive decline in PD-MCI. Furthermore, a review paper by
Muzzio et al. (2009) reported that due to the neuroanatomical position
of CA1 region that renders its ability to compare information that is
processed through the trisynaptic loop with new information arriving
directly from the cortex, it has been posited that the CA1 region may
serve as an attentional gate. Taken together, atrophy in CA1 could exac-
erbate cognitive decline, specifically attentional deficits, in PD-MCI; and
that progressive atrophy could potentially promote the conversion of
MCI to dementia in PD.
At baseline, PD-MCI also showed reduced volumes in fimbria, a
white matter structure that extends from the alveus and eventually
forms the fornix, and HATA, which lies in the medial region of the
hippocampus and is superior to the other subfields. Several animal
studies have postulated that the projection of fimbria-fornix to the
dorsal part of basal nucleus in amygdala plays an important role in
mediating the amygdala-hippocampus interactions (Gary-Bobo and
Bonvallet, 1977; Jas et al., 2000). Lesions to either the fimbria or
the amygdala could disrupt the network and eventually result in vi-
suospatial and object discrimination dysfunction (Chai and White,
2004; Wible et al., 1992). These animal studies could potentially
translate to human studies; therefore, the reduction of volumes in
fimbria and HATA in this study could be an early biomarker to visuo-
spatial dysfunction in PD-MCI.
PD-converters had greater pathological alterations in CA2–3 over
18 months compared to PD-stable; they also showed that baseline vol-
umes of GC-DG, CA4, parasubiculum, and HATA were predictive of the
conversion from PD-NCI to PD-MCI over 18 months. Previous imaging
studies, including postmortem evidence showed specific degeneration
in the CA2–3 hippocampal subregion in both demented and non-de-
mented PD subjects (Pereira et al., 2013; Mattila et al., 1999; Harding
and Halliday, 2001). This implies that atrophy of CA2–3 hippocampal
subfield could be a significant hallmark across the different neurode-
generative stages of PD. Additionally, the results from PD-converters
could be explained by two major pathways: mossy fibers pathway
and the hippocampal-amygdala connections. Any disruption to the
mossy fibers pathway – where mossy fibers within GC-DG make nu-
merous synapses en passage with the dendrites in CA4 and then in
CA3 subfields – could lead to a deregulation of glutamate release in
the mossy fibers (Acsády et al., 1998; Amaral et al., 2007). Evidence
has also demonstrated that altered glutamatergic neurotransmission
and neuronal metabolic dysfunction could result in pathophysiological
motor and cognitive dysfunction in PD (Cenci, 2014). In turn, baseline
volumes of GC-DG and CA4might be able to predict greater glutamater-
gic deafferentation in the conversion of PD-NCI to PD-MCI. Moreover,
animal studies have shown that axonal projections from the lateraland basolateral nuclei of amygdaloid complex to the entorhinal cortex
to the ventral part of subiculum and the parasubiculum could modulate
information processingwithin the hippocampal formation (Pikkarainen
et al., 1999). Consequently, it is postulated that in humans, any atrophy
within the parasubiculum and HATA might disrupt the integrity of the
hippocampal-amygdala network affecting the information processed.
Collectively, disruptions to the mossy fibers pathway and hippocam-
pal-amygdala pathway due to reduction of volumes in CA3, GC-DG,
CA4, parasubiculum, or HATA could promote cognitive dysfunctions
and serve as early indicators and potential biomarkers for the conver-
sion from PD-NCI to PD-MCI.
Limitations in this study should be acknowledged. Firstly, this study
has a relatively short follow-up of 18 months, which did not allow us to
study progression to dementia. Moreover, this short follow-up has also
created variability in the study as many of these PD subjects may not
experience atrophy in a linear way or are at a high risk but have not
yet reached a significant rapid decline of cognition. Additionally, the
relatively short follow-up of 18 months inhibited us from studying the
progression of the PD subjects to dementia. However, as the cohort is
currently being followed-up, impact of hippocampal subfields atrophy
on progression to PD-dementia will be investigated at a later time
point. Secondly, this study has a relatively small sample size. Hence, re-
sults from this study needs to be reproduced in larger studies.Moreover,
due to the lack of control subjects, we could not make comparisons be-
tween the changes found in PD subjects and the physiological ageing. As
such, these findings need to be confirmed in larger prospective studies
with an additional group of well-matched healthy controls. Lastly, due
to the lack of T2 sequence, onlyMPRAGE sequenceswere used.MPRAGE
lacks the relevant landmarks for the precise subfield boundaries and
hence the segmentation process is purely inferential.
In addition, there are limitations of the atlas used in FreeSurfer 6.0.
The Bayesian inferential method deployed on FreeSurfer 6.0 has not
been robustly validated against a gold standardmethod, such asmanual
segmentation (Wolf et al., 2015). Furthermore, even with ultra-high
resolution MRI, there are boundaries such as the interfaces between
the CA fields along the pyramidal layer of the hippocampus or the
CA4/GC-DG interface that cannot be seen. However, it is imperative to
note that this remains as a widely known problem in the hippocampal
subregion MRI literature wherein remains the discrepancy and
variability in subregion definitions, especially when comparing the
heterogeneous manual annotations used in previous voxel-based
morphometry studies (Iglesias et al., 2015). Therefore, volumetric re-
sults from the individual subregions must be interpreted with caution.
Despite so, automatic segmentation using FreeSufer still provides highly
useful information of the hippocampus as the ex vivo atlas significantly
outperforms the in vivo atlas in the segmentation of the whole hippo-
campus. This allow us to detect distinct subtle changes within the
hippocampus in PD and to understand how the architecture and inter-
connections of the hippocampus in affecting the pathophysiology of
PD. Moreover, by using an automated segmentation, it allows for a
more reproducible and automatic fashion of segmenting the hippocam-
pus into its subregions instead of the typical labor intensive and biased
method of manual hippocampus segmentation.
It is important to note that as clinical criteria for PD-MCI do not dif-
ferentiate whether cognitive impairment is due to PD or Alzheimer's
disease (AD) pathological process, these hippocampal subfield changes
suggest a possible underlying AD pathology among PD patients. This is
especially so when the hippocampus has shown to be an early area to
be affected in AD. Future studies should investigate theunderlyingpath-
ological processes behind hippocampal subfields atrophy in PD patients
as this will allow for better disease management.
Another strength in this study includes the novelty of tracking the
progression of hippocampal atrophy and to investigate the association
between atrophic subregions and cognition in the PD subjects overtime.
These allowed us to understand the pathophysiological mechanisms
that underlie cognitive impairment in PD and potentially use specific
42 H. Foo et al. / NeuroImage: Clinical 14 (2017) 37–42hippocampal subfields as biomarkers in predicting cognitive impair-
ment in PD.
5. Conclusions
Current literature does not fully incorporate the intricately connected
hippocampal subfields networks due to the complexity of its architec-
ture; however, such anatomical knowledge is imperative for under-
standing the functional contribution of each subfield. In this present
study, PD-MCI showed significant atrophy in specific reduction of hippo-
campal subfield volumes. More importantly, baseline volume of GC-DG,
CA4, parasubiculum, and HATA could be important biomarkers in the
prediction of conversion from PD-NCI to PD-MCI. Consistent with
emerging data showing the pivotal role of hippocampus in cognition in
PD, this study provides strong evidence that structural changes in the
hippocampus could result in cognitive deficits. Therefore, the hippocam-
pus could aid in early detection of cognitive impairment in PD subjects.
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